Our data suggest that ApoC‐III and ApoE oxidation are early events associated with MASLD development; despite correlating with liver damage, we did not observe a worsening alongside the disease spectrum thus potentially discounting the direct contribution of apolipoproteins oxidation in the progression of the disease. The gene discussed is APOE; the disease is metabolic dysfunction-associated steatotic liver disease.